Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography

Trial Profile

Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2019

At a glance

  • Drugs Ferumoxytol (Primary)
  • Indications Pulmonary embolism
  • Focus Diagnostic use
  • Most Recent Events

    • 20 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 23 Aug 2018 Planned initiation date changed from 1 Aug 2018 to 1 Sep 2018.
    • 20 Jul 2018 Protocol has been amended to change the trial phase from I/II to Phase III
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top